Literature DB >> 1717173

The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.

.   

Abstract

The Queen's Gambit is an opening move in chess that provides a variety of aggressive options to the player electing it. This report represents a similar gambit (the Sicilian Gambit) on the part of a group of basic and clinical investigators who met in Taormina, Sicily to consider the classification of antiarrhythmic drugs. Paramount to their considerations were 1) dissatisfaction with the options offered by existing classification systems for inspiring and directing research, development, and therapy, 2) the disarray in the field of antiarrhythmic drug development and testing in this post-Cardiac Arrhythmia Suppression Trial (CAST) era, and 3) the desire to provide an operational framework for consideration of antiarrhythmic drugs that will both encourage advancement and have the plasticity to grow as a result of the advances that occur. The multifaceted approach suggested is, like the title of the article, a gambit. It is an opening rather than a compendium and is intended to challenge thought and investigation rather than to resolve issues. The article incorporates first, a discussion of the shortcomings of the present system for drug classification; second, a review of the molecular targets on which drugs act (including channels and receptors); third, a consideration of the mechanisms responsible for arrhythmias, including the identification of "vulnerable parameter" that might be most accessible to drug effect; and finally, clinical considerations with respect to antiarrhythmic drugs. Information relating to the various levels of information is correlated across categories (i.e., clinical arrhythmias, cellular mechanisms, and molecular targets), and a "spread sheet" approach to antiarrhythmic action is presented that considers each drug as a unit, with similarities to and dissimilarities from other drugs being highlighted. A complete reference list for this work would require as many pages as the text itself. For this reason, referencing is selective and incomplete. It is designed, in fact, to provide sufficient background information to give the interested reader a starting frame of reference rather than to recognize the complete body of literature that is the basis for this article.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717173     DOI: 10.1161/01.cir.84.4.1831

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  44 in total

1.  Pharmacological Therapy of Cardiac Arrhythmias.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-11       Impact factor: 2.300

2.  Negative chronotropic and inotropic effects of class I antiarrhythmic drugs assessed in isolated canine blood-perfused sinoatrial node and papillary muscle preparations.

Authors:  A Sugiyama; S Takehana; R Kimura; K Hashimoto
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

Review 3.  The impact of recent ion channel science on the development and use of antiarrhythmic drugs.

Authors:  M N Langan
Journal:  Curr Cardiol Rep       Date:  1999-11       Impact factor: 2.931

Review 4.  Mechanisms of antiarrhythmic drug actions and their clinical relevance for controlling disorders of cardiac rhythm.

Authors:  Uma Srivatsa; Nitin Wadhani; Bramah N Singh
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

Review 5.  Subclassification of class I antiarrhythmic drugs: enhanced relevance after CAST.

Authors:  T J Campbell
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

6.  Frequency-dependent action of antiarrhythmic drugs: the useful concept of periodical ligand binding.

Authors:  J Weirich
Journal:  Basic Res Cardiol       Date:  1992 May-Jun       Impact factor: 17.165

7.  Probing kinetic drug binding mechanism in voltage-gated sodium ion channel: open state versus inactive state blockers.

Authors:  Krishnendu Pal; Gautam Gangopadhyay
Journal:  Channels (Austin)       Date:  2015       Impact factor: 2.581

Review 8.  Blockade of cardiac potassium and other channels by antihistamines.

Authors:  E Delpón; C Valenzuela; J Tamargo
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

Review 9.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

Review 10.  A benefit-risk assessment of class III antiarrhythmic agents.

Authors:  Bente Brendorp; Oledyg Pedersen; Christian Torp-Pedersen; Naji Sahebzadah; Lars Køber
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.